Unravelling the Antifibrinolytic Mechanism of Action of the 1,2,3-Triazole Derivatives.

ABSTRACT: A new family of antifibrinolytic drugs has been recently discovered, combining a triazole moiety, an oxadiazolone, and a terminal amine. Two of the molecules of this family have shown activity that is greater than or similar to that of tranexamic acid (TXA), the current antifibrinolytic gold standard, which has been associated with several side effects and whose use is limited in patients with renal impairment. The aim of this work was to thoroughly examine the mechanism of action of the two ideal candidates of the 1,2,3-triazole family and compare them with TXA, to identify an antifibrinolytic alternative active at lower dosages. Specifically, the antifibrinolytic activity of the two compounds (1 and 5) and TXA was assessed in fibrinolytic isolated systems and in whole blood

SUBMITTER: Rabada Y 

PROVIDER: S-EPMC11241262 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature